Literature DB >> 19758166

IL-18 activity in systemic lupus erythematosus.

Flavia Favilli1, Consuelo Anzilotti, Lucia Martinelli, Paola Quattroni, Salvatore De Martino, Federico Pratesi, Detlef Neumann, Silke Beermann, Daniela Novick, Charles A Dinarello, Diana Boraschi, Paola Migliorini.   

Abstract

Interleukin-18 (IL-18) is an inflammation-related cytokine that plays a central role both in innate defense reactions and in Th1 activation and specific immune responses. Increased levels of IL-18 can be detected in biological fluids and organs of individuals affected by several autoimmune pathologies, as well as in autoimmune animal models. In this review, the role of IL-18 in systemic lupus erythematosus (SLE) is critically examined, including its possible role in the pathogenesis of disease. In SLE, increased levels of IL-18 have been found in serum/plasma of affected persons, which positively correlated with disease severity. The possibility that circulating IL-18 levels are predictive of renal damage has been proposed, suggesting that IL-18 may be a prognostic marker of renal involvement useful to identify patients at risk of renal failure. The evaluation of urinary levels of free active IL-18 indeed suggests a correlation with the degree of renal involvement. The possible pathogenic role of IL-18 in lupus has been studied in a mouse model of progressive disease, which makes possible the identification, at the level of the different affected organs, of IL-18 changes preceding disease development and those appearing after disease onset. It can be concluded that IL-18 has a multifaceted role in autoimmune lupus, being apparently involved both in the effector phases of the late organ damage and, in some organs, in the initial pathogenic events. Therapeutic strategies targeting IL-18 in autoimmunity are under development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758166     DOI: 10.1111/j.1749-6632.2009.04742.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  32 in total

1.  Nailfold capillaroscopy assessment of microcirculation abnormalities and endothelial dysfunction in children with primary or secondary Raynaud syndrome.

Authors:  Joanna Latuskiewicz-Potemska; Antonina Chmura-Skirlinska; Ryszard J Gurbiel; Elzbieta Smolewska
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

2.  Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus.

Authors:  J Michelle Kahlenberg; Seth G Thacker; Celine C Berthier; Clemens D Cohen; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2011-11-04       Impact factor: 5.422

3.  Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients.

Authors:  Dawei Hu; Xiaoqian Liu; Shunle Chen; Chunde Bao
Journal:  Clin Rheumatol       Date:  2010-02-08       Impact factor: 2.980

4.  Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis.

Authors:  Binwu Ying; Yunying Shi; Xiaofu Pan; Xingbo Song; Zhunchun Huang; Qian Niu; Bei Cai; Lanlan Wang
Journal:  Mol Biol Rep       Date:  2010-04-28       Impact factor: 2.316

Review 5.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Annu Rev Med       Date:  2014-11-05       Impact factor: 13.739

Review 6.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

Review 7.  IL-18 in inflammatory and autoimmune disease.

Authors:  Saikiran K Sedimbi; Thomas Hägglöf; Mikael C I Karlsson
Journal:  Cell Mol Life Sci       Date:  2013-07-27       Impact factor: 9.261

Review 8.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 9.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

Review 10.  Macrophage activation syndrome in the era of biologic therapy.

Authors:  Alexei A Grom; AnnaCarin Horne; Fabrizio De Benedetti
Journal:  Nat Rev Rheumatol       Date:  2016-03-24       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.